Skip to content

Liquidia Corporation LQDA Business Segments — Program Expenses

Similar metrics at other companies

Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$27.59M-1.1%
Protagonist Therapeutics logo
PTGXSingle Reportable — Cost Of Revenue Discovery Expenses Excluding Employee Expense Benefit And Allocation Share Based Compensation Expenses
$8.51M+127%
ImmunityBio, Inc. logo
IBRXReportable Segment — Operating Expenses
$113.76M+40.6%
Protagonist Therapeutics logo
PTGXSingle Reportable — Cost Of Revenue Development Expenses Excluding Employee Expense Benefit And Allocation Share Based Compensation Expenses
$17.47M+35.4%
Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Vaxcyte, Inc. logo
PCVXReportable Segment — Operating Expenses
$345.85M+91.3%

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Cash & equivalents$222.8M+31.2%
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
Enterprise value$6.1B+184%
P/S21.9×-147×

Profitability

See full
Gross margin58.1%-18.7pp
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Reported directly by Liquidia Corporation in its filing.

Tagged under the XBRL concept lqda:ProgramExpenses.

The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's business segments — program expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's business segments — program expenses?
Liquidia Corporation (LQDA) reported business segments — program expenses of $21.66M in Q1 2026.
How has Liquidia Corporation's business segments — program expenses changed year-over-year?
Liquidia Corporation's business segments — program expenses increased by 64.4% year-over-year, from $13.18M to $21.66M.
What is the long-term trend for Liquidia Corporation's business segments — program expenses?
Over 2 years (2023 to 2025), Liquidia Corporation's business segments — program expenses has grown at a 44.1% compound annual growth rate (CAGR), from $36.35M to $75.48M.
What does business segments — program expenses mean?
This metric captures the direct costs associated with specific research, development, and clinical trial programs within the business segment. It reflects the company's investment in advancing its product pipeline and proprietary technology platforms. Monitoring these expenses helps investors assess the efficiency and progress of the company's R&D initiatives.